This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaste, M. Articles by Neuvonen, P. J. Search for Related Content PubMed PubMed Citation Articles by Kaste, M. Articles by Neuvonen, P. J.

Stroke, Vol 14, 525-530, Copyright © 1983 by American Heart Association

ARTICLES

Increase of low serum concentrations of high-density lipoprotein (HDL) cholesterol in TIA-patients treated with phenytoin

M Kaste, A Muuronen, EA Nikkila and PJ Neuvonen

Serum high density lipoprotein (HDL) cholesterol and other lipoproteins were measured in 27 TIA-patients with a mean age of 49 +/- 10 years before and during phenytoin therapy. The pretreatment concentrations of HDL-cholesterol (mmol/l, mean +/- SD) were lower (p less than 0.001) in male (1.03 +/- 0.25) and in female patients (1.15 +/- 0.44) than in healthy male (1.28 +/- 0.34) and female controls (1.52 +/- 0.31) respectively. After one month's phenytoin therapy HDL cholesterol concentrations reached normal levels (men 1.33 +/- 0.38, women 1.61 +/- 0.27) and after 9 months of therapy even surpassed them (men 1.47 +/- 0.27, p less than 0.05; women 1.91 +/- 0.33, p less than 0.01). Percent increase of HDL cholesterol after 9 months of therapy was 42 +/- 25 in men and 68 +/- 46 in women. There was a positive correlation (r = 0.43, p less than 0.05) between serum phenytoin level and increase of HDL cholesterol. HDL/LDL cholesterol ratio increased (p less than 0.01) also during 9 months of therapy (men from 0.26 +/- 0.05 to 0.36 +/- 0.10, women from 0.26 +/- 0.07 to 0.43 +/- 0.13) and showed a positive correlation (r = 0.91, p less than 0.001) with increase of serum HDL cholesterol. The HDL cholesterol levels achieved have been maintained with a mean serum phenytoin level of 5.6 +/- 3.6 mg/l. Phenytoin induced increase in serum HDL levels should not yet be equated with protection against atherosclerosis.

This article has been cited by other articles:

				M. Castro-Gago, M. I. Novo-Rodriguez, M. O. Blanco-Barca, A. Urisarri-Ruiz de Cortazar, J. Rodriguez-Garcia, S. Rodriguez-Segade, and J. Eiris-Punal Evolution of Serum Lipids and Lipoprotein (a) Levels in Epileptic Children Treated With Carbamazepine, Valproic Acid, and Phenobarbital J Child Neurol, January 1, 2006; 21(1): 48 - 53. [Abstract] [PDF]

				M. Miller, R. G. Burgan, L. Osterlund, J. P. Segrest, and D. W. Garber A Prospective, Randomized Trial of Phenytoin in Nonepileptic Subjects With Reduced HDL Cholesterol Arterioscler Thromb Vasc Biol, December 1, 1995; 15(12): 2151 - 2156. [Abstract] [Full Text]

				Y. Henkin, J. A. Como, and A. Oberman Secondary Dyslipidemia: Inadvertent Effects of Drugs in Clinical Practice JAMA, February 19, 1992; 267(7): 961 - 968. [Abstract] [PDF]